Delving into the Latest Updates on pUDK-HGF(Beijing Institute of Radiation Medicine) with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms-

Target

HGF

Action

modulators

Mechanism

HGF modulators(Hepatocyte growth factor modulators)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization

Beijing Institute of Radiation Medicine

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

pUDK‐HGF, recombinant plasmid DNA encoding human HGF (hepatocyte growth factor), is a potential agent for gene therapy of ischaemic disease. Production of pUDK‐HGF is essential for its clinical application. In the present paper, a large‐scale manufacturing process was developed, including fermentation, cell harvest, alkaline lysis, capturing plasmid DNA with Q‐Sepharose XL chromatography, size‐exclusion chromatography on a Sephacryl S1000 column and refining with Source 15Q anion‐exchange chromatography. The quality criteria of pUDK‐HGF such as purity, concentration, homogeneity, residual RNA, chromosomal DNA, contaminated protein, endotoxin and HGF expression efficacy all were analysed and met the requirements for pharmaceutical‐grade plasmid DNA.

100 Deals associated with pUDK-HGF(Beijing Institute of Radiation Medicine)

Login to view more data